Lantheus Holdings, Inc. $LNTH Shares Acquired by Ashton Thomas Private Wealth LLC

Ashton Thomas Private Wealth LLC boosted its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 68.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 21,312 shares of the medical equipment provider’s stock after purchasing an additional 8,632 shares during the quarter. Ashton Thomas Private Wealth LLC’s holdings in Lantheus were worth $1,093,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the stock. Elevation Point Wealth Partners LLC purchased a new stake in shares of Lantheus during the 2nd quarter valued at $26,000. Osterweis Capital Management Inc. purchased a new position in shares of Lantheus in the 2nd quarter worth $36,000. First Horizon Corp acquired a new position in Lantheus in the third quarter valued at $26,000. EverSource Wealth Advisors LLC grew its position in Lantheus by 190.2% during the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock valued at $87,000 after acquiring an additional 698 shares during the period. Finally, EMC Capital Management acquired a new stake in Lantheus during the second quarter worth about $93,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on LNTH shares. Mizuho lifted their price objective on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Truist Financial lifted their price target on shares of Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Finally, Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Five investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $78.00.

Lantheus Trading Up 0.0%

NASDAQ LNTH opened at $64.89 on Friday. The stock has a market cap of $4.30 billion, a P/E ratio of 27.26 and a beta of -0.08. The company’s fifty day simple moving average is $65.59 and its 200-day simple moving average is $59.73. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.29.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.27. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The business had revenue of $384.01 million during the quarter, compared to analyst estimates of $363.42 million. During the same period last year, the business earned $1.70 EPS. The business’s revenue was up 1.4% on a year-over-year basis. Equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.